FDA Partners with Commonwealth Informatics to Build Drug Safety Analysis Platform

February 4, 2016

FDA & Commomwealth Information Partner to Build Platform to Analyze Drug Safety Data

On January 28, 2016, the FDA and Commonwealth Informatics entered into a two-year agreement where they will work together to develop a platform to help the Agency assess drug safety data. The agreement was signed as part of the FDA’s 21st Century Review Initiative, which is a set of standards that was developed in an effort to organize and integrate the drug review process, as well as ensure that all decision makers are heard.

Commonwealth Informatics is a Massachusetts-based analytics company that provides cloud-based products and services to regulators, academic professionals, government agencies, and life sciences companies to advance the way clinical data is analyzed. Prior to engaging with the FDA, Commonwealth created a platform called Commonwealth Clinical Data Analytics (CCDA). CCDA was developed in collaboration with the Army Pharmacovigilance Center and is used to monitor drug side effects experienced by more than 15 million patients.

Commonwealth plans to use CCDA as the foundation for its partnership with the FDA, making enhancements to the platform as necessary “to improve the speed and quality of data reviews and the critical analysis of drug safety data.” Commonwealth will do this with assistance from the FDA, as it will be providing scientific, statistical, and clinical support to help the company make improvements to the platform. By working together, the FDA and Commonwealth ultimately hope to “improve the speed, quality, and transparency of analyzing drug safety data,” allowing regulators to make more informed decisions.

At the project’s outset, Commonwealth will host the program using its internal cloud infrastructure. As the platform progresses it will be integrated with some of the FDA’s custom-developed tools and programs, such as the openFDA platform. As such, Commonwealth eventually plans to turn the platform over to FDA, who will host the program internally at some point in the future.

Are you in the process of developing a new drug? Are you preparing for a pre-IND or EOP2 meeting? Are you developing an IND or NDA for submission to the FDA? We can help. Using our proprietary approach, we have a track record of helping our clients achieve positive outcomes with FDA. To learn more about our services and how we can help you, contact us today.



General Regulatory Drug Approval

February 4, 2016

FDA Meetings: How to Prepare for FDA Type B Meetings

The Food and Drug Administration has laid out a drug development continuum that includes three milestones, or Type B meetings. Earliest is the Pre-IND Meeting, the second is the End of Phase 2 (EOP2)...

Read More
General Regulatory Drug Approval

February 4, 2016

Four Benefits of Requesting an FDA Pre-IND Meeting

Although not required, a Pre-IND Meeting is a critical milestone, one that is highly recommended by the FDA. The goal of the meeting is to receive general agreement from FDA that your drug...

Read More
Agency Alerts General Regulatory

February 4, 2016

FDA Issues Warning Letter After Kim Kardashian Posts Selfie

On July 19, 2015, Kim Kardashian posted a “selfie” to her Instagram and Twitter accounts. You may be thinking “She does that all the time… Why would that matter to the FDA?” The selfie in question...

Read More